6 results on '"Schott, Matthias"'
Search Results
2. Impact of renal function and demographic/anthropomorphic variables on peak thyrotropin after recombinant human thyrotropin stimulation: a stepwise forward multiple-regression analysis.
- Author
-
Hautzel H, Pisar E, Lindner D, Schott M, Grandt R, and Müller HW
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Body Surface Area, Female, Humans, Hypothyroidism diagnosis, Hypothyroidism etiology, Kidney drug effects, Male, Metabolic Clearance Rate, Middle Aged, Recombinant Proteins blood, Recombinant Proteins pharmacokinetics, Regression Analysis, Renal Insufficiency blood, Renal Insufficiency complications, Retrospective Studies, Thyroid Gland drug effects, Thyroid Gland physiopathology, Thyroid Neoplasms complications, Thyroid Neoplasms physiopathology, Thyroid Neoplasms therapy, Thyrotropin blood, Young Adult, Kidney physiopathology, Renal Insufficiency physiopathology, Thyrotropin pharmacokinetics
- Abstract
Background: When applying the recommended standard doses of recombinant human thyrotropin (rhTSH) in the diagnostic/therapeutic management of patients with differentiated thyroid cancer (DTC), the resulting peak TSH levels vary extensively. Previous studies applying multivariate statistics identified patient-inherent variables influencing the rhTSH/peak TSH relation. However, those results were inconclusive and partly conflicting. Notably, no independent role of renal function was substantiated, despite the fact that the kidneys are known to play a prominent role in TSH clearance from blood. Therefore, the study's aim was to investigate the impact of renal function on the peak TSH concentration after the standard administration of rhTSH used in the management of thyroid cancer. The second objective was to calculate a ranking regarding the effect sizes of the selected variables on the peak TSH., Methods: There were 286 patients with DTC included in the study. Univariate and multivariate analyses were performed, testing the correlation of serum creatinine and glomerular filtration rate (GFR) as surrogate parameters of renal function, age, sex, weight, height, and body surface area (BSA) with the peak TSH level. In six additional patients, the subsequent TSH pharmacokinetics after the TSH peak were measured and qualitatively compared., Results: By univariate analyses, TSH correlated negatively with BSA, GFR, weight, and height, and positively with age, female sex, and serum creatinine (p<0.001). On the multivariate analysis, the stepwise forward multiple linear regression revealed BSA and renal function as the two most influential independent variables, followed by age, sex, and height. The pharmacokinetic datasets indicated that these identified parameters also influence the TSH decline over time., Conclusion: Identifying those patients with a favorable combination of parameters predicting a high-peak TSH is the first step toward an individualization of rhTSH dosing. Additionally, the subsequent TSH decrease over time needs to be taken into account. A complete understanding of the interrelation of the identified key parameters and both the TSH peak and subsequent TSH pharmacokinetics might allow for a more personalized rhTSH dosage strategy to achieve sufficient TSH levels instead of the fixed dosing procedure used at present.
- Published
- 2013
- Full Text
- View/download PDF
3. Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper.
- Author
-
Giovanella, Luca, Clark, Penelope M., Chiovato, Luca, Duntas, Leonidas, Elisei, Rossella, Feldt-Rasmussen, Ulla, Leenhardt, Laurence, Luster, Markus, Schalin-Jäntti, Camilla, Schott, Matthias, Seregni, Ettore, Rimmele, Herald, Smit, Jan, and Verburg, Frederik A.
- Subjects
THYROGLOBULIN ,THYROID cancer patients ,BIOLOGICAL assay ,THYROTROPIN ,ENDOCRINOLOGY - Abstract
Differentiated thyroid cancer (DTC) is the most common endocrine cancer and its incidence has increased in recent decades. Initial treatment usually consists of total thyroidectomy followed by ablation of thyroid remnants by iodine-131. As thyroid cells are assumed to be the only source of thyroglobulin (Tg) in the human body, circulating Tg serves as a biochemical marker of persistent or recurrent disease in DTC follow-up. Currently, standard follow-up for DTC comprises Tg measurement and neck ultrasound combined, when indicated, with an additional radioiodine scan. Measurement of Tg after stimulation by endogenous or exogenous TSH is recommended by current clinical guidelines to detect occult disease with a maximum sensitivity due to the suboptimal sensitivity of older Tg assays. However, the development of new highly sensitive Tg assays with improved analytical sensitivity and precision at low concentrations now allows detection of very low Tg concentrations reflecting minimal amounts of thyroid tissue without the need for TSH stimulation. Use of these highly sensitive Tg assays has not yet been incorporated into clinical guidelines but they will, we believe, be used by physicians caring for patients with DTC. The aim of this clinical position paper is, therefore, to offer advice on the various aspects and implications of using these highly sensitive Tg assays in the clinical care of patients with DTC. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Reply to Drs. Kiaei and Molinaro Regarding the Publication "Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation".
- Author
-
Allelein, Stephanie, Diana, Tanja, Schott, Matthias, and Kahaly, George J.
- Subjects
THYROTROPIN receptors ,RECEPTOR antibodies ,IMMUNOASSAY ,BIOLOGICAL assay ,THYROTROPIN ,PHARMACOLOGY ,THYROID hormones - Abstract
Dear Editor, Drs. Kiaei and Molinaro 1 put forth two criticisms of the manuscript published by us 2. They state that the experimental design of this study is flawed and that the authors falsely claim that negative Thyretain™ TSI Reporter BioAssay results for two Graves' diseases patients undergoing drug treatments means the absence of stimulating antibodies. To substantiate this claim Drs. Kiaei and Molinaro point out that the manufacturer of the Thyretain TSI Reporter BioAssay clearly states in the package insert that "[t]he effects of various drug therapies on the performance of this Kit have not been established" 1. Second, the package insert explicitly states that "[a] negative result does not exclude the possibility of the presence of TSI" and results of the test should be interpreted in conjunction with information available from other clinical information, such as physical symptoms and thyroid hormone testing, as recommended by the American Thyroid Association (ATA)". Furthermore they state that the "authors of the manuscript did not consider the manufacturer's warning regarding the intended patient population and the ATA guidelines regarding the interpretation of the test results in conjunction with other clinical information. Instead, the authors based their conclusions on the negative Thyretain TSI Reporter BioAssay results and ignored the patients' clinical history of Graves' disease." [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Clinical review about TRAb assay's history
- Author
-
Zöphel, Klaus, Roggenbuck, Dirk, and Schott, Matthias
- Subjects
- *
AUTOANTIBODIES , *THYROTROPIN , *HORMONE receptors , *AUTOIMMUNE thyroiditis , *THYROGLOBULIN , *THYROID eye disease , *LUMINESCENCE immunoassay , *POLYETHYLENE glycol - Abstract
Abstract: Commercial assays to measure thyroid stimulating hormone (TSH) receptor (TSHR) autoantibodies (TRAb) have been available for the serological diagnosis of autoimmune thyroid diseases (AITD) for several years. The widespread assessment of this parameter has identified Graves'' disease (GD) as a common organ-specific autoimmune disease. Within the present article we aim to review immunobiological and epidemiological aspects as well as diagnostic methods available for the detection of TRAb. Over the last decade, TRAb detection in GD became more sensitive since TRAb assays were being largely improved by named research groups. Therefore, functional assay (fas) and diagnostic sensitivity of current TRAb assays will be discussed. Within the second part of this review we will focus on clinical applications of TRAb measurement for outcome prediction of GD as well as the importance of this method to distinguish GD from other AITD. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
6. Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies
- Author
-
Hermsen, Derik, Broecker-Preuss, Martina, Casati, Marco, Mas, Jordi Camara, Eckstein, Anja, Gassner, Dieter, van Helden, Josef, Inomata, Keiko, Jarausch, Jochen, Kratzsch, Jürgen, Mann, Klaus, Miyazaki, Naoko, Navarro Moreno, Miguel Angel, Murakami, Tsukasa, Roth, Heinz-Jürgen, Noh, Jaeduk Yoshimura, Scherbaum, Werner A., and Schott, Matthias
- Subjects
- *
THYROTROPIN , *AUTOANTIBODIES , *MONOCLONAL antibodies , *GRAVES' disease , *IMMUNOASSAY , *MEDICAL practice , *PATIENTS - Abstract
Abstract: Background: Graves'' disease (GD) is mediated by autoantibodies which bind to the TSH receptor (TRAb). The aim of the present study was to evaluate the technical performance of the first fully automated immunoassay for TRAb detection. Methods: The Elecsys® Anti-TSHR immunoassay utilizes a porcine TSH receptor (TSHR) and the human thyroid stimulating monoclonal TSHR autoantibody M22. Results: Intraassay and total imprecision CV were determined between 1.4%–14.9%, and 2.4%–28.8%, respectively. Using the 20% CV criteria the functional sensitivity was found at 0.73 IU/L. The median CV at the cut-off (1.75 IU/L) was found to be 11%. Comparison studies with five TRAb immunoassays yielded slopes and intercepts between 1.02–1.48, and −0.74–0.56, respectively. Correlation coefficients were determined between 0.895 and 0.978. ROC plot analysis of patients with GD, patients with other thyroid disorders and healthy controls revealed an AUC of 0.99 resulting in a sensitivity of 97% and a specificity of 99% at a TRAb level of 1.75 IU/L. Conclusion: The evaluation of the TRAb immunoassay generated homogeneous performance data and demonstrated a high degree of comparability to established TRAb assays. The automated TRAb assay represents a major improvement of thyroid testing in clinical practice. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.